《大行》建銀國際首次覆蓋蜜雪集團(02097.HK) 目標價620.5元
建銀國際發表報告,首次覆蓋蜜雪集團(02097.HK)給予「優於大盤」評級,目標價為620.5元。在對高性價比優質產品需求不斷增長的背景下,尤其是在宏觀經濟不確定時期,該行相信蜜雪集團在高增長的大眾市場中的主導地位將使其保持持續增長。
報告指,蜜雪集團的顯著成功,深植於其在中國現制飲品市場中快速增長的大眾市場領域的戰略主導地位。憑藉其強大的供應鏈,蜜雪集團的平均售價顯著低於主要競爭對手,甚至接近主要即飲飲料公司的平均售價。這一定價策略精準地迎合了大眾市場中價格敏感但又渴望高品質的消費群體,以及在宏觀經濟不確定性下,消費降級帶來的對高性價比產品的日益增長的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.